1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals

Core Insights - Vertex Pharmaceuticals has seen its shares rise over 2,000% in the past 20 years, with no analysts expecting a decline in the coming year [1] - The company is the sole provider of cystic fibrosis treatments, with a significant market presence and a promising future [3][8] Financial Performance - Vertex Pharmaceuticals reported second-quarter sales of $2.96 billion, reflecting a 12% year-over-year increase [2] - The stock has a consensus price target of $496.05, indicating a potential gain of approximately 26% from its closing price on September 12, 2025 [1] Product and Market Position - Vertex's latest treatment, Alyftrek, is a once-daily combination therapy that enhances CFTR protein function, launched in 2024 [5] - The company is expected to maintain market exclusivity for a considerable time due to the recent launch of Alyftrek [5] Demographics and Impact - Approximately 109,000 people globally are affected by cystic fibrosis, with around 75,000 relying on Vertex's treatments [3][8] - Advances in treatment have significantly improved life expectancy for cystic fibrosis patients, with many expected to live to age 65 [4]